立方体使用和痴呆风险:系统审查和更新的元分析
Fernando Luiz Westphal Filho1, Paulo Roberto Moss Lopes1, Artur Menegaz de Almeida2
1Department of Clinical Surgery School of Medicine Federal University of Amazonas Manaus Amazonas Brazil.
Alzheimer's & dementia (New York, N. Y.)
|January 17, 2025
概括
根据一项大型元分析,他类药物显著降低了痴呆风险,包括阿尔茨海默病和血管痴呆症. 这些发现突显了他类药物在预防痴呆症方面的神经保护潜力.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 公共卫生 公共卫生
背景情况:
- 痴呆症影响全球5500万,预计到2050年将增加三倍.
- 用于心血管健康的他类药物可能提供神经保护.
- 之前关于他类药物和痴呆风险的研究产生了相互矛盾的结果.
研究的目的:
- 系统地审查和元分析他类药物使用与痴呆症风险之间的关联.
- 评估他类药物对阿尔茨海默病 (AD) 和血管痴呆症 (VaD) 的影响.
- 根据性别,他类型和糖尿病状况进行子组分析.
主要方法:
- 按照PRISMA指南进行系统审查和元分析.
- 在PubMed,Embase和Cochrane数据库中进行了搜索.
- 包括55项观察性研究,涉及700多万名患者.
主要成果:
- 立方体使用与痴呆风险显著降低有关 (HR 0.86;95% CI:0.82至0.91).
- 对阿尔茨海默病的风险有所降低 (HR 0.82;95% CI:0.74至0.90).
- 在2型糖尿病患者,长期使用他类药物 (>3年) 和亚洲人群中发现了显著的益处. 罗斯瓦斯塔丁显示出最明显的效果.
结论:
- 静止剂的使用在预防痴呆症方面显示出显著的神经保护潜力.
- 这些发现支持他类药物作为潜在的公共卫生策略,用于预防痴呆症.
- 需要进一步的随机临床试验来证实这些关联并指导临床实践.
相关概念视频
01:22Alzheimer's Disease: Treatment
160
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
160
01:30Dementia
93
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
93
01:26Alzheimer's Disease: Overview
439
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
439
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
95
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
95
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
526
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
526